{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (2''S'')-6-Amino-2-<nowiki>[[</nowiki>(2''R'')-2-<nowiki>[[</nowiki>(2''R'')-2-<nowiki>[[</nowiki>(2''S'')-2-[(2-amino-2-methylpropanoyl)amino]-3-(4''H''-imidazol-4-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide.
| image = ipamorelin.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Intravenous]], [[subcutaneous injection|subcutaneous]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 2 hours<ref name="GobburuAgersø1999">{{cite journal|last1=Gobburu|first1=Jogarao V. S.|last2=Agersø|first2=Henrik|last3=Jusko|first3=William J.|last4=Ynddal|first4=Lars|title=Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers|journal=Pharmaceutical Research|volume=16|issue=9|year=1999|pages=1412–1416|issn=0724-8741|doi=10.1023/A:1018955126402}}</ref>
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 170851-70-4
| CAS_supplemental = 
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 20754357
| DrugBank_Ref = 
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Y9M3S784Z6
| ChemSpiderID_Ref = 
| ChemSpiderID = 8007390

<!--Chemical data-->
| C=38 | H=49 | N=9 | O=5
| molecular_weight = 711.85296 g/mol
|  smiles = CC(C)(C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N)N
|  StdInChI = 1S/C38H49N9O5/c1-38(2,41)37(52)47-32(21-28-22-42-23-43-28)36(51)46-31(20-25-15-16-26-12-6-7-13-27(26)18-25)35(50)45-30(19-24-10-4-3-5-11-24)34(49)44-29(33(40)48)14-8-9-17-39/h3-7,10-13,15-16,18,22-23,29-32H,8-9,14,17,19-21,39,41H2,1-2H3,(H2,40,48)(H,42,43)(H,44,49)(H,45,50)(H,46,51)(H,47,52)/t29-,30+,31+,32-/m0/s1
|  StdInChIKey = NEHWBYHLYZGBNO-BVEPWEIPSA-N
| synonyms = 
}}

'''Ipamorelin''' ([[International Nonproprietary Name|INN]]) (developmental code name '''NNC 26-0161''') is a [[peptide]] selective [[agonist]] of the [[growth hormone secretagogue receptor|ghrelin/growth hormone secretagogue receptor]] (GHS) and a [[growth hormone secretagogue]].<ref name="MoulinRyan2007">{{cite journal|last1=Moulin|first1=Aline|last2=Ryan|first2=Joanne|last3=Martinez|first3=Jean|last4=Fehrentz|first4=Jean-Alain|title=Recent Developments in Ghrelin Receptor Ligands|journal=ChemMedChem|volume=2|issue=9|year=2007|pages=1242–1259|issn=1860-7179|doi=10.1002/cmdc.200700015|pmid=17520591}}</ref><ref name="RaunHansen1998">{{cite journal|last1=Raun|first1=K|last2=Hansen|first2=B.|last3=Johansen|first3=N.|last4=Thogersen|first4=H|last5=Madsen|first5=K|last6=Ankersen|first6=M|last7=Andersen|first7=P.|title=Ipamorelin, the first selective growth hormone secretagogue|journal=European Journal of Endocrinology|volume=139|issue=5|year=1998|pages=552–561|issn=0804-4643|doi=10.1530/eje.0.1390552}}</ref> It is a [[pentapeptide]] with the [[amino acid sequence]] Aib-His-<small>D</small>-2-Nal-<small>D</small>-Phe-Lys-NH<sub>2</sub> that was derived from [[GHRP-1]].<ref name="IsidroCordido2006">{{cite journal|last1=Isidro|first1=Maria|last2=Cordido|first2=Fernando|title=Growth Hormone Secretagogues|journal=Combinatorial Chemistry & High Throughput Screening|volume=9|issue=3|year=2006|pages=175–180|issn=1386-2073|doi=10.2174/138620706776055458}}</ref>

Ipamorelin significantly increases [[Blood plasma|plasma]] [[growth hormone]] (GH) levels in both animals and humans.<ref name="GobburuAgersø1999" /><ref name="RaunHansen1998" /><ref name="Estrada2002">{{cite journal|last1=Estrada|first1=R. Cañete|last2=Jiménez-Reina|first2=L.|last3=de la Torre|first3=M.J.|last4=Bernal|first4=J.|title=Chronic In Vivo Ipamorelin Treatment Stimulates Body Weight Gain and Growth Hormone (GH) Release In Vitro in Young Female Rats|volume=6|issue=1|year=2002|pages=37–46|issn=1136-4890|url=http://www.researchgate.net/publication/28093664_Chronic_in_vivo_Ipamorelin_treatment_stimulates_body_weight_gain_and_growth_hormone_(GH)_release_in_vitro_in_young_famale_rats}}</ref> In addition, ipamorelin stimulates body weight gain in animals.<ref name="Estrada2002" /> Like pralmorelin and GHRP-6, ipamorelin does not affect [[prolactin]], [[follicle-stimulating hormone]] (FSH), [[luteinizing hormone]] (LH), or [[thyroid-stimulating hormone]] (TSH) levels.<ref name="RaunHansen1998" /> However, unlike [[pralmorelin]] (GHRP-2) and [[GHRP-6]], but similarly to [[growth hormone-releasing hormone]] (GHRH), ipamorelin does not stimulate the secretion of [[adrenocorticotropic hormone]] (ACTH) or [[cortisol]], and is highly selective for inducing the secretion only of GH.<ref name="RaunHansen1998" />

Ipamorelin was originally developed by [[Novo Nordisk]], and was investigated in [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s by [[Helsinn Therapeutics]] for the treatment of [[postoperative ileus]], but was discontinued due to lack of efficacy.<ref name="BeckSweeney2014">{{cite journal|last1=Beck|first1=David E.|last2=Sweeney|first2=W. Brian|last3=McCarter|first3=Martin D.|title=Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients|journal=International Journal of Colorectal Disease|volume=29|issue=12|year=2014|pages=1527–1534|issn=0179-1958|doi=10.1007/s00384-014-2030-8}}</ref><ref name="AdisInsight">{{cite web | url = http://adisinsight.springer.com/drugs/800011351 | title = Ipamorelin | author = AdisInsight | accessdate = 10 June 2015}}</ref>

==See also==
* [[Anamorelin]]
* [[Capromorelin]]
* [[Examorelin|Examorelin (hexarelin)]]
* [[GHRP-6|GHRP-6 (SKF-110679)]]
* [[Ibutamoren|Ibutamoren (MK-677)]]
* [[Macimorelin]]
* [[Pralmorelin|Pralmorelin (GHRP-2)]]
* [[Relamorelin]]
* [[SM-130,686]]
* [[Tabimorelin]]

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800011351 Ipamorelin - AdisInsight]


{{GH/IGF-1 axis signaling modulators}}

[[Category:Ghrelin receptor agonists]]
[[Category:Growth hormone secretagogues]]
[[Category:Hormonal agents]]
[[Category:Imidazoles]]
[[Category:Naphthalenes]]
[[Category:Peptides]]
[[Category:World Anti-Doping Agency prohibited substances]]
[[Category:Abandoned drugs]]


{{systemic-hormonal-drug-stub}}